Skip to content

ONCOVISTA INNOVATIVE THERAPIES, INC: 10-Q filed 2013-05-14

What ONCOVISTA INNOVATIVE THERAPIES, INC reported in its quarterly report filed 2013-05-14 (fiscal Q1 2013): 25 published measures, 52 facts as tagged in accession 0001144204-13-028768.

This filing

Form
10-Q (quarterly report)
Filed
2013-05-14
Fiscal period
fiscal Q1 2013
Accession
0001144204-13-028768 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ONCOVISTA INNOVATIVE THERAPIES, INC filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2013-03-31315,169USD
At 2012-12-31575,266USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2013-03-31-2,122,258USD
At 2012-12-31-1,679,233USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2013-03-31224,633USD
At 2012-12-31511,687USD
At 2012-03-311,664,797USD
At 2011-12-312,125,229USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2013-01-01 to 2013-03-31-448,189USD90
2012-01-01 to 2012-03-31-659,428USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2013-01-01 to 2013-03-31-287,054USD90
2012-01-01 to 2012-03-31-460,432USD91

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2013-01-01 to 2013-03-310USD90
2012-01-01 to 2012-03-310USD91

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2013-03-31-22,356,696USD
At 2012-12-31-21,908,507USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2013-03-312,334USD
At 2012-12-313,464USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2013-01-01 to 2013-03-311,964USD90
2012-01-01 to 2012-03-3118,797USD91

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2013-03-31312,835USD
At 2012-12-31571,802USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2013-01-01 to 2013-03-3136USD90
2012-01-01 to 2012-03-313,369USD91

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2013-03-312,437,427USD
At 2012-12-312,254,499USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2013-03-311,054,256USD
At 2012-12-31933,547USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2013-01-01 to 2013-03-31394,649USD90
2012-01-01 to 2012-03-31487,601USD91

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2013-01-01 to 2013-03-31237,817USD90
2012-01-01 to 2012-03-31298,825USD91

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2013-03-3121,627,868shares
At 2012-12-3121,627,868shares

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2013-03-3139,458USD
At 2012-12-3139,458USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2013-03-3137,124USD
At 2012-12-3135,994USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2013-03-311,181,283USD
At 2012-12-311,172,752USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2013-03-3188,202USD
At 2012-12-3160,115USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2013-01-01 to 2013-03-31156,832USD90
2012-01-01 to 2012-03-31188,776USD91

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2013-01-01 to 2013-03-311,130USD90
2012-01-01 to 2012-03-311,745USD91

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2013-01-01 to 2013-03-31-53,540USD90
2012-01-01 to 2012-03-31-171,827USD91

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2013-01-01 to 2013-03-310USD90
2012-01-01 to 2012-03-310USD91

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2013-01-01 to 2013-03-31120,709USD90
2012-01-01 to 2012-03-3111,269USD91

Inspect the source

Entity
ONCOVISTA INNOVATIVE THERAPIES, INC / CIK 0001094847
Captured
SEC response SHA-256
034ecc655296ec55707e21b2011e7bc05aab2b1bd1d5e47c9d631e0e4310eac5

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001094847.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))